Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs

Amycretin

MARKETED

unimolecular GLP-1 + amylin receptor agonist

5
graded findings
4
effect domains
Evidence spread
High evidence 0Moderate evidence 3Low evidence 2Very low evidence 0

Amycretin is shown as a marketed evidence record where applicable. Findings describe observed research and regulatory records; they do not provide treatment advice.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Amycretin MARKETED
Weight change Decrease
Moderate evidence

Oral amycretin: first-in-human pharmacodynamic weight reduction over 12 wk

Gasiorek A et al. Lancet 2025;406:135-148 Source
PopulationOverweight/obese (BMI 25-39.9), phase 1 first-in-human (n=144), single + multiple ascending oral doses (NCT05369390)
Fundingindustry - Novo Nordisk
Scope limitsconference/abstract-level; identifier not fully verified; small sample (N~144); surrogate/exploratory endpoint
Comparatorsplacebo
Amycretin MARKETED
Weight change Decrease
Low evidence

Subcutaneous amycretin produced large dose-dependent weight loss over 20-36 wk

Dahl K, Toubro S et al. Amycretin, unimolecular GLP-1 and amylin receptor agonist s.c.: p... Source
PopulationOverweight/obese (BMI 27-39.9), phase 1b/2a (n=125; 101 amycretin), up to 36 wk, RCT placebo-controlled (NCT06064006)
Fundingindustry - Novo Nordisk (trial sponsor; inferred from registration trial)
Scope limitssingle-centre/referral-enriched
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Amycretin MARKETED
Glycaemic control Decrease
Moderate evidence

Fasting plasma glucose change assessed as exploratory PD endpoint (oral)

Gasiorek A et al. Lancet 2025;406:135-148 Source
PopulationPhase 1 oral first-in-human (n=144)
Fundingindustry - Novo Nordisk
Scope limitsconference/abstract-level; identifier not fully verified; small sample (N~144); surrogate/exploratory endpoint
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Amycretin MARKETED
Pharmacology and mechanism Not directional
Moderate evidence

First-in-class single-molecule GLP-1R + amylin receptor agonist; both oral and s.c. formulations; dose-proportional exposure

Gasiorek A et al. Lancet 2025;406:135-148 Source
PopulationPhase 1 oral and phase 1b/2a s.c.
Fundingindustry - Novo Nordisk
Scope limitsconference/abstract-level; identifier not fully verified; small sample (N~144); surrogate/exploratory endpoint
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Amycretin MARKETED
Gastrointestinal tolerability Increase
Low evidence

Predominantly GI TEAEs, mild-to-moderate, dose-dependent; all resolved

Dahl K, Toubro S et al. Amycretin, unimolecular GLP-1 and amylin receptor agonist s.c.: p... Source
Populations.c. phase 1b/2a (n=125) and oral phase 1 (n=144)
Fundingindustry - Novo Nordisk (trial sponsor; inferred from registration trial)
Scope limitssingle-centre/referral-enriched
Comparatorsplacebo